Hunter C Smith has sold RYTM and made no open-market buys since Jul 2022

Hunter C. Smith is an individual and the Chief Financial Officer (CFO) and Treasurer of Rhythm Pharmaceuticals, Inc. (RYTM), a biopharmaceutical company focused on rare neuroendocrine diseases, since August 2017.( Aged 57, he previously served as interim CEO from March to July 2020, leading the company through FDA submissions and market challenges.( Under his tenure, Smith orchestrated the company's initial public offering and raised over $1 billion in capital, significantly contributing to corporate strategy and growth in rare disease therapeutics.(

With over 30 years of global finance and management experience across industries, Smith joined Rhythm from Celgene Corporation, where he was Vice President of Finance and CFO of the Inflammation and Immunology Business Unit, overseeing the global launch of Otezla® and the integration of Receptos, Inc..( He has recently engaged in insider trading, selling shares worth approximately $702,744 in early February 2026, and is scheduled to speak at the Guggenheim Emerging Outlook: Biotech Summit 2026.(

Written by Perplexity from public sources.